STAAR Surgical (NASDAQ:STAA) Given New $37.00 Price Target at Wedbush

Posted by Brenda Bartman on Aug 13th, 2026

STAAR Surgical (NASDAQ:STAA – Get Free Report) had its price target cut by equities research analysts at Wedbush from $40.00 to $37.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Wedbush’s target price would indicate a potential upside of 45.61% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. Wells Fargo & Company upped their price target on shares of STAAR Surgical from $16.00 to $25.00 and gave the company an “equal weight” rating in a report on Friday, May 15th. Stifel Nicolaus lifted their price objective on STAAR Surgical from $18.00 to $31.00 and gave the stock a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Mizuho raised their target price on STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Finally, Canaccord Genuity Group upped their price target on STAAR Surgical from $27.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and an average target price of $26.61.

Read Our Latest Stock Analysis on STAA

STAAR Surgical Price Performance

Shares of STAAR Surgical stock opened at $25.41 on Thursday. The firm has a fifty day simple moving average of $26.98 and a 200-day simple moving average of $24.08. The company has a current ratio of 5.12, a quick ratio of 4.31 and a debt-to-equity ratio of 0.09. STAAR Surgical has a 1-year low of $15.59 and a 1-year high of $35.87. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -59.09 and a beta of 1.26.

STAAR Surgical (NASDAQ:STAA – Get Free Report) last posted its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.05. The business had revenue of $93.52 million for the quarter, compared to analyst estimates of $78.72 million. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. STAAR Surgical’s revenue was up 119.6% compared to the same quarter last year. During the same period last year, the business posted ($1.10) EPS. On average, sell-side analysts expect that STAAR Surgical will post 0.13 earnings per share for the current year.

Institutional Trading of STAAR Surgical

Institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of STAAR Surgical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock worth $518,000 after buying an additional 1,267 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in STAAR Surgical by 33.4% during the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock worth $9,606,000 after acquiring an additional 136,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of STAAR Surgical by 11.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock valued at $2,175,000 after acquiring an additional 12,841 shares during the period. Creative Planning boosted its stake in shares of STAAR Surgical by 19.9% in the 2nd quarter. Creative Planning now owns 15,695 shares of the medical instruments supplier’s stock valued at $263,000 after purchasing an additional 2,606 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of STAAR Surgical by 183.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 153,371 shares of the medical instruments supplier’s stock worth $2,574,000 after purchasing an additional 99,218 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about STAAR Surgical

Here are the key news stories impacting STAAR Surgical this week:

Positive Sentiment: STAAR reported second-quarter revenue of approximately $93.5 million, exceeding the roughly $90.6 million analyst estimate and increasing more than 100% year over year. Adjusted earnings also surpassed consensus in one widely cited measure, at $0.31 per share versus an expected $0.21, compared with a $0.07 loss a year earlier. STAAR Surgical Surpasses Q2 Earnings and Revenue Estimates
Positive Sentiment: Management expects to finish 2026 with well over $200 million in cash, supporting financial flexibility for growth initiatives. It also plans to shift all China-bound supply to Switzerland, which could reduce exposure to geopolitical, tariff and regional production risks over time. STAAR Surgical Plans Cash and Supply-Chain Changes
Neutral Sentiment: The company’s revenue growth reflects continued demand for its implantable collamer lenses, but investors are evaluating procedure demand and the mix of sales across China and other geographic markets. The earnings call provided additional context on operating performance and 2026 priorities. STAAR Surgical Q2 2026 Earnings Call Transcript
Negative Sentiment: Reported GAAP earnings were cited at $0.16 per share, below the $0.22 consensus estimate, despite the revenue beat. That bottom-line miss likely contributed to the stock’s decline as investors weighed profitability and execution rather than focusing solely on sales growth. STAAR Surgical Earnings Report
Negative Sentiment: Moving 100% of China supply to Switzerland may improve resilience, but the transition could introduce manufacturing, logistics and cost risks in the near term.

STAAR Surgical Company Profile

(Get Free Report)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.